Lead Product(s): CAN106
Therapeutic Area: Hematology Product Name: CAN106
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: WuXi Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2021
CAN106 is a recombinant human monoclonal antibody that specifically binds to and neutralizes C5 and is intended to prevent the formation of membrane attack complexes on red blood cell surfaces, thereby reducing cell lysis and other symptoms associated with PNH.